Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report

With a novel mechanism of action and unprecedented clinical efficacy in multiple tumor types, immune checkpoint inhibitors (ICI) have revolutionized cancer therapy. Yet these promising treatments have also introduced new challenges. Compared to the well-characterized and predictable toxicities of cytotoxic chemotherapy or molecularly targeted therapies, ICI-induced immune-related adverse events (irAE) affect a far broader range of organ systems, may mimic other clinical conditions, and may occur at almost any point in treatment. Clinical characteristics generally not considered relevant to other cancer treatments, such as body mass index, history of autoimmune disease, and exposure to antibiotics, may influence both the efficacy and tolerability of ICI treatment [1‐4].

Perhaps one of the most disconcerting features of ICI administration is the potential for pseudoprogression. While early changes in tumor dimensions reliably indicate the benefits of chemotherapy and targeted therapy, in a subset of patients treated with ICI transient radiographic worsening may precede subsequent benefit [5]. Some studies indicate that pseudoprogression may occur in up to 10% of patients receiving ICI therapy [6].

In advanced non-small cell lung cancer (NSCLC), the combination of anti-programmed death 1 (PD-1) plus chemotherapy or the combination of anti-PD-1 and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) plus chemotherapy offers the opportunity to deliver fast-acting cytotoxic agents along with slower but potentially more durably acting ICI. However, as demonstrated in the case presented here, pseudoprogression may still occur with such regimens.

This study was approved by the UT Southwestern Institutional Review Board (IRB #STU 082015-053).

The patient received two cycles of carboplatin-pemetrexed plus pembrolizumab. He tolerated treatment well, with no high-grade toxicities. However, repeat imaging after two cycles demonstrated concern for disease progression, with enlarging lesions in the lung, liver, adrenal gland, neck, and skull. Although clear growth was observed, it did not meet the threshold for hyperprogression, which is most commonly defined as at least a doubling of tumor growth rate [7, 8]. Given primary disease progression and the high burden of disease, the clinical team planned to change treatment to docetaxel plus ramucirumab. In the weeks following discontinuation of the carboplatin-pemetrexed plus pembrolizumab regimen, the patient reported improved symptoms and energy level, which were attributed to waning of treatment-associated toxicities.

On the day prior to the planned initiation of docetaxel plus ramucirumab, repeat imaging was performed to provide a near-term baseline for subsequent efficacy assessment. The chest CT demonstrated improvement compared to the prior CT image. Accordingly, instead of changing the treatment regimen, the clinical team proceeded with two additional cycles of carboplatin-pemetrexed plus pembrolizumab, following which further response was noted on the chest CT and PET images (Figs. 1, 2). Subsequently, maintenance therapy was initiated with pemetrexed plus pembrolizumab, which was changed to pembrolizumab monotherapy after one cycle due to serum creatinine elevation and fatigue. Since then, the patient has received six cycles of maintenance pembrolizumab, and disease control remains ongoing at 6 months after the initiation of combination chemotherapy plus ICI. Aside from requiring a mild levothyroxine dose adjustment, the patient has had no substantial toxicities.

To our knowledge, this article represents the first reported case of pseudoprogression in a patient treated with combination chemotherapy plus ICI. With ICI alone, the reported incidence of pseudoprogression is 2–6% [9, 10]. How to distinguish these cases remains an ongoing area of research. While it has been suggested that clinical symptom trends (worsening in true progression vs. stable or improving in pseudoprogression) may distinguish these processes, it is not clear how reliable this strategy is. Indeed, pseudoprogression has been recognized in patients months after clinical deterioration, treatment cessation, and hospice referral [11]. PET-CT images, both of which document inflammatory changes and neoplastic tissue, routinely demonstrate fluorodeoxyglucose (FDG) uptake but may also fail to differentiate pseudoprogression and true progression [12]. If feasible, biopsy of an enlarging lesion may provide insight, with pseudoprogression featuring CD3, CD4, and CD8 T cell lymphoid infiltrates [13]. More convenient than tissue sampling, cell-free DNA (cfDNA) burden kinetics as a means to ascertain pseudoprogression represents an area of active investigation.

Concern for pseudoprogression resulted in specific recommendations for radiographic monitoring of ICI efficacy. In contrast to conventional response evaluation criteria in solid tumors (RECIST), immune-related response criteria (irRC) incorporate moderate enlargement of pre-existing lesions and appearance of new lesions into the domain of disease control [14]. However, recent NSCLC clinical trials of combination chemotherapy plus ICI have employed standard RECIST [15, 16]. Additionally, these trials perform and act on early radiographic efficacy assessments (typically after 2 cycles, approximately 6 weeks after treatment initiation), in contrast to the later and confirmatory assessments recommended for immunotherapy [17].

If pseudoprogression occurs in a patient treated with combination chemotherapy plus ICI, does this imply chemotherapy resistance? Alternatively, chemotherapy might have efficacy, but radiographic manifestation of immune cell influx outweighs that of tumor regression, resulting in tumor enlargement on imaging studies. In this case, while combination carboplatin-pemetrexed was continued for two more cycles and single-agent pemetrexed for one cycle of maintenance therapy thereafter, ICI monotherapy with pembrolizumab has resulted in months of ongoing disease control. For now, whether cytotoxic agents should be discontinued due to potential lack of efficacy when pseudoprogression occurs with combination chemoimmunotherapy will need to be considered on a case-by-case basis.

How to determine which cases are experiencing true progression versus pseudoprogression, which is attributed to an early influx of immune cells resulting in apparent tumor enlargement, represents a true challenge for clinicians [18]. Ideally, all patients could continue ICI after initial progression. Such an approach would not only ensure subsequent pseudoprogression and clinical benefit are not missed, but would also provide insight into the true incidence of this phenomenon. In reality, however, many patients cannot afford to continue potentially ineffective treatment in the setting of advanced malignancy.

To our knowledge, this is the first reported case of pseudoprogression with combination chemoimmunotherapy, which serves as an important reminder that this rare phenomenon may occur in various clinical contexts. Indeed, the potential for early disease control from cytotoxic agents has served as the rationale for such regimens as ipilimumab + nivolumab combined with two initial cycles of platinum doublet chemotherapy [19]. Currently, there is no reliable means to predict or diagnose these rare events. Given the potential long-term benefits of ICI therapy and the potential harms of unchallenged cancer growth, clinicians face high stakes when choosing whether to continue or change treatment. This is all the more true when one considers that pseudoprogression has been associated with improved survival [20]. There remains a clear need for practical and accurate means to recognize pseudoprogression. This case report represents one novel presentation of pseudoprogression with combination chemotherapy with immunotherapy. There may be other presentations of this phenomenon; therefore, more studies, analyzing why presentations like this exist should be conducted.